ORDER
This Order grants Defendant E.I. du Pont de Nemours & Co.’s (Du Pont) supplemental motion for summary judgment (document # 112). In a previous Order dated April 15, 1992, this Court denied said defendant’s motion for summary judgment with regard to the claims at issue here.
1
However, further
Plaintiffs’ implied warranty claim fails because there can be no warranty claim against Du Pont. The undisputed facts show that there was no expectation on behalf of Vitek or Dr. Homsy that one of PTFE’s ordinary purposes was its use in medical implants. Because Vitek can have no warranty claim against Du Pont, there can be none from which the plaintiffs can derive such a claim.
Plaintiffs negligence and strict liability “inadequacy of warnings” theories are to be considered together. Many courts, including this one as noted in the April 15th order, find that there is no practical difference between an action in negligence for breach of one’s duty to warn and an action in strict liability for a product defect due to inadequate warning or labeling.
See
Court Order dated April 15, 1992. The bulk supplier doctrine is an absolute defense to these warning claims. Moreover, summary judgment is proper if Du Pont can demonstrate that the evidence in the record so conclusively establishes each element of the bulk seller doctrine that there is no genuine issue of material fact.
See e.g. Higgins v. E.I. DuPont de Nemours, Inc.,
The purpose of summary judgment is to avoid unnecessary trials when there is no dispute as to the facts before the court.
Zweig v. Hearst Corp.,
The moving party bears the burden of informing the court of the basis for its motion, together with evidence demonstrating the absence of any genuine issue of material fact.
Celotex Corp. v. Catrett,
In evaluating the appropriateness of summary judgment, three steps are necessary: (1) determining whether a fact is material; (2) determining whether there is a genuine issue for the trier of fact, as determined by the documents submitted to the court; and (3) considering that evidence in light of the appropriate standard of proof.
Anderson, supra.
As to materiality, only disputes over facts that might affect the outcome of the suit under the governing law will properly preclude the entry of summary judgment. Factual disputes which are irrelevant or unnecessary will not be considered.
Id.
at 248,
Summary judgment is not a disfavored procedural shortcut, but an integral part of the federal rules as a whole.
Id.
When faced with a motion for summary judgment, the material before the court “must be viewed in the light most favorable to the
A Negligence and Strict Liability and the Bulk Supplier Defense
This Court was previously concerned that a disclaimer alone was insufficient to invoke a bulk supplier defense adequate to withstand summary judgment. The augmented record combined with this Court’s satisfaction that the bulk supplier defense is an appropriate defense under Nevada law relieve the Court of any of its earlier concerns.
The relevant question in determining the sufficiency of a bulk supplier defense is whether the bulk supplier was objectively reasonable in relying on a knowledgeable intermediary to provide a warning to ultimate users.
Sara Lee Corp. v. Homasote Co.,
The record has now been supplemented with information which was not in the record at the time of Du Pont’s original motion for summary judgment. The undisputed facts now conclusively establish the presence of all the prerequisites described by this court for the application, as a matter of law of the bulk seller/sophisticated user doctrine. It is clear and undisputed that: 1) Du Pont sold only raw industrial materials in bulk form. 2) Du Pont’s raw materials contained no “manufacturing defect.” 3) Du Pont’s raw materials are inherently inert and safe for their ordinary industrial purposes; 4) Du Pont’s vendee, Dr. Homsy and Vitek were experts with regard to Du Pont’s materials and knew their properties. They were fully trained and knowledgeable about the published concerns regarding the use of PTFE inside a joint where it might be abraded. 5) In addition to their independent knowledge, Du Pont told Dr. Homsy and Vitek what it knew about concerns expressed by others regarding PTFE inside a loaded hip joint. Du Pont did no independent testing, and expressly disclaimed the suitability of its polymer products for medical applications. 6) Du Pont’s vendees, Dr. Homsy and Vitek, acknowledged that they already knew what Du Pont told them and confirmed to Du Pont that they were fully capable of passing on their knowledge to their purchasers. 7) The FDA had a pervasive statutory and regulatory scheme, the purpose of which was to ensure the safety of medical devices such as the products Dr. Homsy and Vitek were making with Du Pont’s raw materials. 8) Dr Homsy and Vitek had a legal, criminally-enforceable, duty to tell the FDA relevant facts and they committed in writing to Du Pont that they would fulfill their duties as federally-regulated medical device manufacturers. Vitek had a common law duty to warn the patients doctors about relevant risks in the use of its finished products and this duty was also regulated by the FDA. 9) The FDA published what it knew about the same concerns as Du Pont was aware of, and still allowed Vitek’s product to be sold.
The record now reflects the undisputed facts required to conclusively establish the presence of all the prerequisites described by the Court, for the application, as a matter of law, of the bulk seller doctrine. It is clear that Du Pont was reasonable in believing that the intermediary knew of the dangers associated with the bulk product and was
B. Implied Warranty Theory
The Court was previously concerned that an expectation that one of PTFE’s ordinary purposes was its use in medical implant materials. The supplemented record shows that no such expectation was ever created. In fact, Du Pont informed Dr. Homsy and Vitek that PTFE was not ordinarily used in such materials. Moreover, Homsy and Vitek acknowledged in writing that Du Pont was not creating in them any such expectation; Homsy and Vitek expressly undertook to make their own determination regarding the use of this material in their patented, proprietary, medical devices; and the FDA had no such expectation.
Plaintiffs implied warranty claim is derivative of Vitek’s rights against Du Pont. Even though vertical privity is no longer necessary in Nevada to support a breach of implied warranty claim for personal injuries against a remote supplier, the user cannot rise any higher than the purchaser through which he obtained the implied warranty.
See Goodbar v. Whitehead Brothers
C. Conclusion
The Court’s questions and reservations outlined in the April 15, 1992 Order have been more than satisfactorily addressed by defendant Du Pont. It was proper for Du Pont to ask this Court to review a supplemental summary judgment motion in light of the new evidence that has been carefully obtained and documented. It is clear from the undisputed facts that summary judgment is appropriate. Plaintiffs opposition failed to create any question of material fact and detrimentally relied on the fact that this Court published the last Order addressing this matter — an order written prior to relevant and material discovery.
IT IS, THEREFORE, HEREBY ORDERED that defendant Du Pont’s motion for supplemental summary judgment (document # 112) is GRANTED. There are no surviving claims against Defendant Du Pont.
Notes
. Summary judgment was granted in part to defendants with regard to plaintiffs’ claims for
